摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

canagliflozin | 1028977-37-8

中文名称
——
中文别名
——
英文名称
canagliflozin
英文别名
(1xi)-1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-D-glucitol;(3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
canagliflozin化学式
CAS
1028977-37-8
化学式
C24H25FO5S
mdl
——
分子量
444.524
InChiKey
XTNGUQKDFGDXSJ-KKEQRHKBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    118
  • 氢给体数:
    4
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS<br/>[FR] TRAITEMENT DE TROUBLES MÉTABOLIQUES CHEZ DES ÉQUIDÉS
    申请人:BOEHRINGER INGELHEIM VETMED
    公开号:WO2014161836A1
    公开(公告)日:2014-10-09
    The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.
    本发明涉及SGLT2抑制剂或其药用可接受形式,用于治疗和/或预防马类动物的代谢紊乱。具体而言,本发明涉及SGLT2抑制剂或其药用可接受形式,用于治疗和/或预防马类动物的胰岛素抵抗、高胰岛素血症、糖耐量受损、血脂异常、脂联素异常、亚临床炎症、全身炎症、低级全身炎症、肥胖和/或局部脂肪堆积。
  • [EN] TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS<br/>[FR] TRAITEMENT DE TROUBLES MÉTABOLIQUES CHEZ DES ANIMAUX CANINS
    申请人:BOEHRINGER INGELHEIM VETMED
    公开号:WO2015110402A1
    公开(公告)日:2015-07-30
    The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes,insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.
    本发明涉及一种或多种SGLT2抑制剂或其药用可接受形式,用于治疗和/或预防犬类动物的代谢紊乱,最好是其中代谢紊乱是从以下组中选择的一种或多种:酮症酸中毒,糖尿病前期,胰岛素依赖型糖尿病,胰岛素抵抗糖尿病,胰岛素抵抗,肥胖,高血糖,高血糖诱导的白内障形成,糖耐量受损,高胰岛素血症,血脂异常,脂联素异常,亚临床炎症,全身炎症,低级全身炎症,肝脂肪变性,胰腺炎炎症,代谢紊乱后果,如高血压,肾功能障碍和/或肌肉骨骼疾病,和/或综合征X(代谢综合征),最好是其中防止或缓解高血糖诱导的白内障形成,和/或最好是其中防止代谢紊乱后果,如高血压,肾功能障碍和/或肌肉骨骼疾病的发展,或减缓进展或缓解。
  • TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS
    申请人:Boehringer Ingelheim Vetmedica GmbH
    公开号:US20150164856A1
    公开(公告)日:2015-06-18
    The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
    本发明涉及一种或多种SGLT2抑制剂或其药用可接受形式,用于治疗和/或预防猫科动物的代谢紊乱,最好是其中代谢紊乱是来自以下组合的一种或多种:酮症酸中毒、糖尿病前期、糖尿病1型或2型、胰岛素抵抗、肥胖、高血糖、糖耐量受损、高胰岛素血症、血脂异常、脂联素异常、亚临床炎症、全身炎症、低级全身炎症、肝脂肪变性、动脉粥样硬化、胰腺炎、神经病变和/或综合征X(代谢综合征)和/或胰岛β细胞功能丧失,其中代谢紊乱的缓解,最好是糖尿病缓解,被实现和/或维持。
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT
    申请人:Fillers Walter Ferdinand Maria
    公开号:US20100099883A1
    公开(公告)日:2010-04-22
    The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    本发明涉及一种新型制备具有抑制钠依赖型葡萄糖转运蛋白(SGLT)活性的化合物的方法。
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2
    申请人:FARINA Vittorio
    公开号:US20110087017A1
    公开(公告)日:2011-04-14
    The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    本发明涉及一种新型制备具有抑制钠依赖型葡萄糖转运蛋白(SGLT)活性的化合物的方法,该蛋白存在于肠道或肾脏中。
查看更多